Introduction {#s0005}
============

Sarcoma is a heterogeneous group of rare tumors whose resistance to radiotherapy, chemotherapy, and molecularly targeted therapies is a major problem in clinical practice hindering major breakthroughs in outcome in the past decades [@bb0005].

New biological knowledge such as the discovery of the important role played by cancer stem cells, genetics, and epigenetic changes on resistance to treatment and eventual prognosis has shown that factors other than those traditionally measured and tested can be detrimental to treatment outcome. Gene expression analysis is increasingly important to understand tumor initiation/progression, giving insight into complex regulatory networks and uncovering new biological processes involved in tumorigenesis.

Reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) is a powerful technique which can detect low levels of mRNA. RT-qPCR is a fast and efficient technique for quantification of the gene expression levels [@bb0010]. However, the results are dependent on appropriate selection of normalization factors to account for errors and differences generated by the multistep process. Variables such as the differences between tissues in overall transcriptional activity need to be controlled in gene expression analysis. The use of internal control (reference) genes is the most commonly used method. Reference genes should be constitutively expressed and should have a stable expression under the experimental conditions and tissue preparation techniques. The expression of internal reference genes varies significantly under different experimental conditions. Therefore, erroneous information could be generated if normalization is based on genes that themselves are regulated or affected by the preparation of tissue samples [@bb0015], [@bb0020].

The clinical material often available for analysis from sarcoma patients is routinely collected formalin-fixed, paraffin-embedded (FFPE) samples processed under different conditions. Factors such as time to fixation, fixation time, and others may contribute to variations in gene expression levels by introducing RNA degradation [@bb0025], [@bb0030]. It is also well known that mRNA from FFPE tissue specimens is poorly preserved and highly degraded [@bb0035]. In rare cancer types such as sarcoma, the FFPE tissue samples are indispensable and invaluable resources for studying gene expression levels. Other studies have shown that using RNA from FFPE tissue samples is feasible [@bb0040], [@bb0045], [@bb0050].

Due to these issues, candidate reference genes must be validated in defined experimental conditions. The purpose of the study was to investigate 22 potential reference genes in FFPE tissue samples with various histology types of sarcoma and to investigate the variation within different samples taken from the same tumor.

Material and Methods {#s0010}
====================

Patient Samples {#s0015}
---------------

Twenty-nine patients treated for sarcoma at the Sarcoma Centre of Aarhus University Hospital between 1991 and 2001 were enrolled in this study. The selected patients' characteristics are presented in [Table 1](#t0005){ref-type="table"}. The tissue samples represented surgical specimens, and for most patients, more than one tissue sample from different locations in the tumor was analyzed. The tissue samples encompassed 82 FFPE tissue samples (between 1 and 6 per patients, with a median of 3 samples per patient) of different histologic types: pleomorphic undifferentiated sarcoma (PUS; *n* = 10), liposarcoma (*n* = 8), leiomyosarcoma (*n* = 2), malignant peripheral nerve sheath tumor (MPNST, *n* = 2), synovial sarcoma (*n* = 2), osteosarcoma (*n* = 1), Ewing (*n* = 1), and fibrosarcoma (*n* = 1). No information about the time from sampling to fixation or the fixation time was available. The tumor tissue samples were chosen based on the pathology report. The tissue sample was excluded from the analysis if more than one gene was not detectable or if the sample was 100% necrotic. One patient was excluded because of 100% normal tissue in all samples. This resulted in excluding 18 samples, and the analysis was done on 64 tissue samples from 25 patients ([Table 1](#t0005){ref-type="table"}).Table 1Sample CharacteristicsPatientHistologyTimeAgeSamplesNo. of Genes% Tumor% Necrosis(No.)(year of biopsy)(No.)not detected[⁎](#tf0010){ref-type="table-fn"}1Ewing19992420/090/900/02Fibrosarcoma1994361010003Leiomyosarcoma19956630/0/0100/100/1000/0/04Leiomyosarcoma19945330/1/6100/90/800/0/205Liposarcoma19996930/0/030/30/060/60/1006Liposarcoma20015430/0/080/80/1000/0/07Liposarcoma19938030/0/0100/20/300/80/708Liposarcoma19944538/0/820/100/10080/0/09Liposarcoma20006430/0/00/0/00/0/010Liposarcoma20015630/0/050/50/600/0/3011Liposarcoma19947730/1/090/80/4010/20/6012Liposarcoma19957730/0/0100/90/1000/10/013PUS199374319/0/10/0/0100/80/014PUS19986430/0/020/20/600/0/015PUS19937330/0/0100/100/600/0/016PUS19935310901017PUS19947640/0/0/085/70/70/7010/0/20/1018PUS19936730/0/075/30/4030/60/6019PUS19936466/0/0/0/0/0100/50/100/95/1000/50/0/0/020PUS19934330/0/080/60/020/40/021PUS19938720/160/4030/5022PUS19936330/0/0100/100/900/0/1023PUS199381315/6/1710/10/1090/90/9023Osteosarcoma19945420/080/900/024MPNST20005130/0/890/100/010/0/025MPNST19983730/0/090/80/200/10/8026Synovial sarcoma19985030/0/095/60/605/0/1027Synovial sarcoma19914530/0/0100/60/700/40/3029Synovial sarcoma1997331990[^1]

RNA Extraction and cDNA Synthesis {#s0020}
---------------------------------

Extraction of total RNA from 7-μm FFPE sections from tissue samples and empty paraffin blocks was performed by the Tissue Preparation System with VERSANT Tissue Preparation Reagents. This is a fully automated, bead-based RNA isolation method (Siemens Healthcare Diagnostics, Tarrytown, NY) as described elsewhere [@bb0055]. Previous data with similar FFPE tissue samples have shown that although the RNA integrity number values are very low due to highly degraded RNA [@bb0035], it is still possible to obtain reproducible qPCR data. Furthermore, the RNA quantity could not be measured on a spectrophotometer because of the elution buffer from the VERSANT Tissue preparation reagents kit (Siemens) which absorbs light at the same wavelength as RNA. However, high-quality and reproducible qPCR data can be obtained using short amplicons (\< 100 bp) and a preamplification step [@bb0035], [@bb0060]. The data from the RT-qPCR were used as an internal quality control, with the quantity and the quality of the RNA reflected in the Cq values of the stable expressed reference genes. The extraction included DNase I treatment to remove potential genomic DNA according to the manufacturer's protocol. cDNA was generated using the High Capacity cDNA Archive Kit (Applied Biosystems \[ABI\], Foster City, CA) according to the manufacturer's protocol. The RNA samples were used within 2 months after preparation and were stored at − 70°C until use. The cDNA were analyzed immediately after preparation.

Primers and RT- qRCR {#s0025}
--------------------

Before RT-qPCR, 10 cycles of preamplification were performed according to the manufacturer's protocol (Taqman Preamp Master Mix, ABI) with modification as described elsewhere [@bb0035]. The reference genes were selected from commonly used reference genes and from the literature with the following search terms using the PubMed database: ("PCR" and "reference" and "sarcoma") or ("genes"\[Mesh\] and "Sarcoma"\[Mesh\] and "reference") or ("aPCR"\[Mesh\] and "Sarcoma"\[Mesh\]) or ("qPCR" and "sarcoma"\[Mesh\]) or ("qPCR" and reference" and "genes") or ("qPCR" and "housekeeping" and "genes"). A further selection was done by excluding all non--cancer-related publications. The reference genes selected for further analysis are shown in [Table 2](#t0010){ref-type="table"}. Assays were selected with an exon junction spanning probe and if possible purchased from ABI. For CALM2 and RPL37A, no ABI assays were suitable, and specifically designed assays were supplied by DNA Technology (Aarhus, Denmark). Assays with amplicons between 60 and 100 bp were chosen (assay numbers or primers and probes are shown in [Table 2](#t0010){ref-type="table"}). The experiment was performed on an ABI PRISM 7900HT in 384-well plates assembled by Biomek 3000 (Beckman Coulter). The qPCR reaction consisted of 3 μl cDNA, 0.75 μl 20 × TaqMan Assay, and 7.5 μl of Taqman Gene Expression Mastermix (ABI), in a total volume of 15 μl. The cDNA was not quantified as we used the results of the RT-qPCR as quality control. The experiment was initiated by one cycle at 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. Samples were loaded in duplicate along with negative controls. Negative controls consisted of both samples from empty paraffin blokes and no template controls. All negative controls where run on each plate. No signal was detected. Positive controls were included consisting of pooled RNA from cell lines. Cq values with a standard deviation above 0.3 between duplicated samples were dismissed, and the RT-qPCR were repeated.Table 2Summary of the Candidate Reference Genes and FunctionGene SymbolGene NameGene FunctionAssay ID[\*](#tf1000){ref-type="table-fn"}Amplicon*ACTB*Actin, βActin, βStructural protein (cytoskeletal)Hs01060665_g163*ACTR3*ARP3 actin-related protin 3 homologMajor constituent of the ARP2/3 complexHs01029161_m172*B2M*β-2-microglobulinBeta-chain of major histocompatibility complex class I moleculesHs00984230_m180*CALM2*Calmodulin 2Calcium-binding messenger protein[\*\*](#tf1005){ref-type="table-fn"}72*CHCHD1*Coiled-coil-helix domain containing 1Nuclear proteinHs00415054_m179*GAPDH*Glyceraldehyde-3-phosphate dehydrogenaseGlycolysisHs02758991_g197*GUSB*Glucuronidase, βDegradation of dermatan and keratan sulfatesPart no 4333767F81*HMBS*Hydroxymethylbilane synthaseHeme synthesis, porphyrin metabolismHs00609293_g162*HPRT1*Hypozanthine phosphoribosyl transferasePurine salvagePart no 4333768T100*IPO8*Importin 8Nuclear protein importHs00183533_m171*MRPL19*Mitochondrial ribosomal protein L19Component of the large ribosomal subunitHs00608519_m172*NDFIP1*Nedd4 family interacting protein 1Integral Golgi membrane proteinsHs00228968_m167*POLR2A*RNA polymerase IICatalyzes the RNA synthesisHs01108291_m186*PPIA*Peptidylpropyl isomerase A*cis*-*trans* isomerization of proline imidic peptid bondsPart no. 4333763F98*PSMC4*Proteasome 26S subunitATP-dependent degradation of ubiquitinated protienHs00197826_m183*PUM1*Pumilio homolog 1translational regulation of mRNAHs00472881_m177*RPL37A*Ribosomal protein L37aProtein synthesis[\*\*\*](#tf1010){ref-type="table-fn"}65*RPLP0*Ribosomal protein, large, P0Structural protein of ribosomesHs00420895_gH76*rRNA18s*[18S ribosomal RNAStructural RNA for the small component of ribosomes]{.ul}Hs03928990_g161*SF3A1*Splicing factor 3a, subunit 1pre-mRNA splicingHs01066327_m164*TBP*TATA box binding protinRNA prolymerase II transcription factorHs00427621_m165*TFRC*Transferrin receptorUptake of ironHs00951083_m166[^2][^3][^4]

Data Analysis and Statistics {#s0030}
----------------------------

The stability of the reference genes was analyzed using the RealTime Statminer (Integromics, Madison, WI), version 20. Cq values above 35 were regarded as below detection limit. Thresholds were set manually in the SDS2.1 software. The GeNorm algorithm calculates an internal control gene-stability measure M. A low value of M means a high relative stability. GeNorm includes the top-ranked genes as reference genes, and the recommended number of reference genes depends on the pairwise variation as described by Vandesompele et al. A pairwise variation under 0.15 was chosen as previously described [@bb0065]. NormFinder collects two genes as reference genes and not necessarily the gene with the best stability scores. The algorithm for NormFinder has been described by Andersen et al. [@bb0070]. [Table 3](#t0015){ref-type="table"} shows the M score calculated by GeNorm and the stability score calculated by NormFinder. For both algorithms, the genes were ranked, and a total rank was established based on all the different analysis entities when analyzing all tissue together, liposarcoma and MHF tissue samples together, and liposarcoma tissue samples and PUS tissue samples as separate groups. The three best ranked genes were used as reference genes.Table 3Ranking of the Genes by Tissue Type and AlgorithmGene SymbolAll Tissue SamplesLiposarcoma and MFH TogetherLiposarcomaMFHOverallM Value[⁎](#tf0005){ref-type="table-fn"}RankS ScoreRankM ValueRankS ScoreRankM ValueRankS ScoreRankM ValueRankS ScoreRankRank*ACTB*0.8970.3950.89110.22110.86130.4912**[0.47]{.ul}**10.3678*ACTR3*1.41140.55140.99140.1880.86120.43100.76100.401112*B2M*1.41150.68181.22160.22131.24170.81181.11190.611917*CALM2***[0.80]{.ul}**30.2510.7950.1330.6760.3860.7190.40104*CHCHD1*0.8350.4170.8060.1650.6350.4080.7280.3446*GAPDH*1.61170.61161.50180.29171.58180.95191.07170.481418*GUSB*1.70180.49110.88100.19102.14190.76170.95150.541614*IPO8***[0.81]{.ul}**40.4912**[0.75]{.ul}**40.1110.6140.2520.85120.50157*MRPL19*[⁎](#tf0005){ref-type="table-fn"}**[0.75]{.ul}**10.3440.8170.144**[0.39]{.ul}**10.364**[0.55]{.ul}**30.2921*NDFIP1*1.28130.4481.36170.31181.20160.65160.697**[0.30]{.ul}**313*POLR2A*1.18110.49100.8790.1320.82110.47110.91140.441311*PPIA*[⁎](#tf0005){ref-type="table-fn"}0.866**[0.29]{.ul}**2**[0.63]{.ul}**10.1770.738**[0.40]{.ul}**70.6440.3663*PUM1*1.55160.60150.94120.22120.93140.57150.98160.571715*RPL37A*1.0890.49130.97130.2815**[0.39]{.ul}**2**[0.37]{.ul}**50.78110.38910*RPLP0*1.0080.4690.878**[0.17]{.ul}**60.79100.4290.88130.43129*rRNA18s*1.21120.64171.15150.28161.00150.56141.07180.611816*SF3A1*[⁎](#tf0005){ref-type="table-fn"}1.16100.396**[0.63]{.ul}**20.189**[0.64]{.ul}**30.231**[0.47]{.ul}**2**[0.27]{.ul}**12*TBP***[0.75]{.ul}**2**[0.33]{.ul}**3**[0.73]{.ul}**3**[0.25]{.ul}**140.7170.3530.6660.3785[^5][^6]

∆Cq values were generated by normalizing the geometric mean of the most stable reference genes. ∆Cq values were calculated in RealTime Statminer version 20.

The intrasamples variation (the standard deviation of single measurements) was calculated and reported with a 95% confidence interval (CI) for each gene. The highest and lowest ∆Cq values were used, and only patients with two or more samples were included. The interclass correlation coefficients were calculated and reported with a 95% CI for each gene to determine the intra and inter variability from each sample. The assumption of the error following a normal distribution was met for all three genes analyzed. The linear regression model was used to calculate the degradation of the mRNA over time. All statistical analysis was performed by using Stata version 12.

Ethics {#s0035}
------

The study has been approved by the Ethics Committee of Denmark (no. 1-10-72-233-12) and the Danish Agency of Data Protection (no. 2012-41-0657).

Results {#s0040}
=======

Of the 82 tissue samples from 29 sarcoma patients, 18 tissue samples were excluded due to more than one missing value in the qPCR analysis. This meant that the potential reference genes could be analyzed in 78% of all tissue samples (64 samples from 25 patients). The Cq value for *PSMC4, HPRT1, HMBS,* and *TFRC* were below the detection limit in 15%, 22%, 23%, and 54% of the analyzed tissue samples, respectively. These genes were therefore excluded from the analysis. [Table 1](#t0005){ref-type="table"} shows the different histologic types and year of biopsy, age of the patient, how many samples from each tumor were collected, and the number of genes not detected in each tissue samples. The last two columns show the percentage of tumor tissue and necrotic tissue in each sample.

To establish which reference was the most stable, the 18 detectable reference genes were analyzed using both the GeNorm and NormFinder algorithm. When all tissue samples were analyzed together, the reference genes found to be the most stable genes were *MRPL19, CALM2 IPO8, TBP* and *TBP, PPIA* for GeNorm and NormFinder, respectively. When analyzing liposarcoma and PUS tissue samples together, the most stable reference genes were *TBP, PPIA, SF3A1, IPO8* and *TBP, RPLPO* for GeNorm and NormFinder, respectively. When analyzing PUS tissue samples alone, the most stable genes were *SF3A1, ACTB, MRPL19* and *NDFIP1, SF3A1* for GeNorm and NormFinder, respectively. When analyzing liposarcoma tissue samples alone, the most stable reference genes were *SF3A1 RPL7A, MRPL19* and *PPIA, RPL37A* GeNorm and NormFinder, respectively. The ranking of the genes is shown in [Table 3](#t0015){ref-type="table"}, and the top-ranking genes, regardless of the algorithm used and tissue included in the analysis, were *MRPL19, PPIA*, and *SF3A1*. The mean Cq value for these three reference genes was 26.9 (95% CI: 26.7 to 27.1). The least stable genes regardless of tissue type and algorithm were *B2M, GAPDH, GUSB, PUM1*, and *rRNA18s*.

The ∆Cq values were calculated using the most stable genes *MRPL19, PPIA*, and *SF3A1* as reference genes for the same three genes to establish whether or not there was a difference in the ∆Cq value between different tissue samples taken from the same patient ([Figure 1](#f0015){ref-type="fig"}). The measurement error or the standard deviation of single measurements (∆Cq value) was 0.61 (95% CI: 0.47 to 0.86), 0.33 (95% CI: 0.26 to 0.47), and 0.44 (95% CI: 0.34 to 0.61) for *PPIA, SF3A1,* and *MRPL19,* respectively. The intraclass correlation coefficients were calculated to find how strongly samples from the same patients resembled each other and show the proportion of total variance within each patient. The intraclass correlation coefficients were 0.57 (95% CI: 0.34 to 0.79), 0.61 (95% CI: 0.40 to 0.82), and 0.47 (95% CI: 0.21 to 0.72) for *PPIA, SF3A1*, and *MRPL19,* respectively. [Supplementary Figure 1](#f0005){ref-type="graphic"} shows the ∆Cq value for each patient against sample number. Each line represents one patient, according to the investigated genes and histologic type of the patients. [Supplementary Figure 2](#f0010){ref-type="graphic"} shows the Bland-Altman plot of difference versus average, comparing the highest and lowest ∆Cq value in each patient. When analyzing liposarcoma alone, the measurement error of the ∆Cq value for each individual was 0.38 (95% CI: 0.25 to 0.78), 0.25 (95% CI: 0.17 to 0.52), and 0.29 (95% CI: 0.19 to 0.58) for *PPIA, SF3A1*, and *MRPL19,* respectively, and for PUS, 0.76 (95% CI: 0.52 to 1.39), 0.43 (95% CI: 0.30 to 0.79), and 0.60 (95% CI: 0.41 to 1.10) for *PPIA, SF3A1*, and *MRPL19,* respectively. [Figure 2](#f0020){ref-type="fig"} shows the variation for all potential reference genes when all samples were normalized to the three most stable genes. The outliner values seen for each gene represent different patients.Figure 1∆Cq value for the three most stably expressed genes for each patient. The ∆Cq values were normalized to the geometric mean of the same three genes. The patient numbers are represented at the *y*-axis. The histologic type for patient number 1 was Ewing sarcoma; for patient number 2, fibrosarcoma; for patient numbers 3 to 4, leiomyosarcoma; for patient numbers 5 to 12, liposarcoma; for patient numbers 13 to 23, PUS; for patient number 24, osteosarcoma; for patient numbers 25 and 26, MPNST; and for patient numbers 27 to 29, synovial sarcoma. Four patients were not included as explained in Material and Methods.Figure 2Median centered ∆Cq values of the 22 studied reference genes, normalized to the three highest-ranking reference genes. All histologic types are represented in this figure. The number of tissue samples for each gene is 64. The *y*-axis represents each gene analyzed.

The raw Cq values were used to establish the degradation rate of the three most stable reference genes. For *PPIA, SF3A1*, and *MRPL19*, the degradation was − 0.37 Cq/year (95% CI: − 0.48 to − 0.27), − 0.34 (95% CI: − 0.44 to − 0.23), and − 0.32 (95% CI: − 0.43 to − 0.23). There was no difference in the slope of the line *P* = .84. This gives an overall half-life of the mRNA of 2.9 years (95% CI: 2.4 to 3.6) ([Figure 3](#f0025){ref-type="fig"}a). When normalization of the three most stable genes to the geometric mean of the same three genes, the degradation was − 0.03 (95% CI: − 0.09 to 0.03), 0.00 (95% CI: − 0.03 to 0.03), and 0.00 (95% CI: − 0.04 to 0.03) for *PPIA, SF3A1*, and *MRPL19*, respectively ([Figure 3](#f0025){ref-type="fig"}b).Figure 3The top figure shows the Cq value for the most stably expressed genes, with the slope of the line representing the degradation of the RNA/year. The bottom figure shows the ∆Cq value for the most stably expressed genes normalized to the geometric mean of the same three genes according to the age for the FFPE tissue blocks. The *y*-axis represents the year of diagnosis.

Discussion {#s0045}
==========

Few studies have addressed the issue of identifying steadily expressed reference genes in sarcoma samples, and to the best of the authors' knowledge, this is the first article to address the problem in FFPE tissue samples from sarcoma patients. Reference gene selection is crucial because it directly influences the interpretation of RT-qPCR data.

According to the Minimum Information for Publication of Quantitative Real-time PCR experiments guidelines [@bb0075], the RNA integrity and purity should be quantified. However, it is well known that the mRNA from FFPE tissue samples is highly degraded and chemical modifications occur during fixation and storage [@bb0025], [@bb0030], [@bb0080]. Although we could not measure the purity and integrity of mRNA in the present study, it was still possible to quantify the expression levels of 18 reference genes in 78% of the tissue samples. This is by itself an important finding because, in the everyday clinic, the FFPE tissue samples often are the only available specimens for research. Due to the low quality of mRNA from old FFPE tissue samples, a proper choice of suitable reference genes is even more important. The selection of reference genes is, however, also highly dependent on the tissues or cells under investigation [@bb0085], [@bb0090], and the expression level of the reference genes can even change with different anatomical regions [@bb0095]. In this study, we used GeNorm and NormFinder to find the most stably expressed reference genes. However, the two methods apply different statistical algorithms, and it was therefore not surprising that they gave somewhat different results. Also, different reference genes are recommended for different histologic types of sarcoma ([Table 3](#t0015){ref-type="table"}). For example, *NDFIP1* was recommended by the NormFinder algorithm when analyzing PUS, but this potential reference gene was poorly ranked when analyzing liposarcoma. Nevertheless, there was general agreement that *MRPL19, PPIA,* and *SF3A1* were within the 10 top-ranking genes regardless of the tissue under investigation or algorithms used. Vandesomple et al. have recommended at least three appropriate reference genes for calculation of a normalization factor because of the variation in the expression of reference genes [@bb0065], which were also used in this study.

The selected reference genes in this study have been shown to be stable expressed in other tissues than sarcoma. In studies investigating reference genes for RT-qPCR experiments using FFPE, *MRPL19* has also been shown to be among the top-ranked reference genes for FFPE samples from both breast [@bb0100] and lung cancer patients [@bb0035]. *PPIA* has been found to be among the most suitable reference genes for normalization in human FFPE epithelial ovarian tissue samples [@bb0105] and from fresh frozen tissue samples in colon cancer [@bb0110]. *SF3A1* has been found to be among the most stable genes in fresh frozen breast cancer specimens [@bb0115].

Because reference genes stably expressed in one cancer type may be less stably expressed in another cancer or under a different experimental condition [@bb0015], [@bb0020], [@bb0085], [@bb0120], we investigated both the intraindividual variation and interindividual variation for all tissues together and for the liposarcoma and PUS separately. These results showed that 57%, 61%, and 47% of the variation in ∆Cq values for *PPIA, SF3A1,* and *MRPL19*, respectively, were a variation between patients rather than within each patient, taking the effect of different histologic types into account. This means that the variation within the samples of each patient is not different than the variation detected between patients, which is desirable when choosing proper reference genes. When looking at the measurement error for all tissues and for PUS and liposarcoma alone, the main intraindividual variation was seen in the PUS samples.

It is important here to note that *GAPDH, B2M,* and *rRNA18s* commonly used as reference genes in other studies were, in fact, the least stable genes regardless of tissue type and analysis algorithms in these FFPE tissue samples. The less stable expression of *GAPDH* is in agreement with previously published results showing an eight-fold difference in expression levels in different tissue types [@bb0015]. Another often used reference gene, *ACTB*, has been shown to have a 22-fold difference in expression levels when comparing different tissue types [@bb0015]. In our experiments, we also found variation among different histologic types.

The total RNA is predominantly composed of rRNA and does not always reflect mRNA content [@bb0125], which is why ribosomal RNA might not be a good reference gene. RNA from FFPE samples is highly degraded, nucleic acids are cross-linked to proteins, and base modifications are introduced during the fixation process [@bb0130]. The half-life of the mRNA was found to be 2.9 years (95% CI: 2.4 to 3.6), which is within the range of previously published results [@bb0135]. When normalizing the three most stable genes to the geometric mean of the same three genes, the effect of degradation was eliminated. However, it is important to analyze the degradation of both target genes and reference genes to ensure the same degradation level.

It is of great importance that every research group investigating gene expression, protein expression, or DNA uses proper reference genes. The results will never get better than the reference genes used in the study. The lack of proper reference gene analysis before conducting gene expression analysis may lead to misleading conclusions and possible undesirable clinical consequences. However, as this study also shows, it might not be possible to exclude or include any specific set of reference genes without testing the genes in the specific experimental setting.

In conclusion, *PPIA, SF3A1*, and *MRPL19* are suitable reference genes for normalization in gene expression profiling studies of FFPE samples from primary soft tissue sarcoma. Although there may be differences in the recommended reference genes according to the histologic sarcoma subtype, it is possible to find reference genes that are stably expressed regardless of the histology of the sarcoma. We recommend that this specific set of reference genes be used and validated in independent experimental setting.

The following are the supplementary data related to this article.Supplementary Figure 1The figure shows the ∆Cq value for each patient against sample number. Each line represents one patient, according to the investigated genes and histologic type of the patients. This is therefore representing the variation within each patient with different tissue samples and the variation between each patient according to the histologic type.Supplementary Figure 2Bland-Altman plot of difference versus average, comparing the ∆Cq value in the highest and lowest ∆Cq value for each patient. The horizontal lines indicate the mean difference and 95% CI.
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[^1]: The following genes were not included in the analysis: *HMBS*, *HPRT1*, *TFRC*, and *PSMC4*.

[^2]: Supplied by ABI.

[^3]: Primer (forward/reverse) GAGCGAGCTGAGTGGTTGTG/AGTCAGTTGGTCAGCCATGCT probe: TCGCGTCTCGGAAACCGGAGC, supplied by DNA Technology.

[^4]: Primer (forward/reverse) TGTGGTTCCTGCATGAAGACA/GTGACAGCGGAAGTGGTATTGTAC probe:TGGCTGGCGGTGCCTGGA, supplied by DNA Technology.

[^5]: The bold and underlined values are the recommended reference genes by the two different algorithms GeNorm and NormFinder when analyzing all tissue samples, liposarcoma and PUS together, and liposarcoma and PUS separately. From these results, an overall ranking was determined, and the three best ranking genes were selected as reference genes.

[^6]: When considering the total rank of the different types analyzed, these 3 genes have the lowest score.
